Fig 1: FABP4 inhibition reduces viral titers across various SARS-CoV-2 variants.(A, B) Representative transmission electron microscopy (TEM) images of (A) HBE cells 48 h after infection with SARS-CoV-2 (WA1/2020, MOI = 1) and treatment with DMSO or CRE-14 (10 μM) (n = 3, biological replicates). (B) Uninfected reconstructed airway epithelium 3D culture treated with DMSO, BMS309403, or CRE-14. (C) Area of double membrane vesicles in infected HBE cells, determined from TEM images in (A). Data displayed as the Fit Spline of the percent frequency distribution. (D) Number of DMVs per image (*p = 0.0242), (E) average DMV area per image, and (F) its frequency distribution quantified from TEM images reconstructed airway epithelium cultures infected with SARS-CoV-2 and treated with DMSO or BMS309403. Statistical analysis is performed using standard t-test (n = 3, biological replicates). Data are shown as the mean ± s.e.m. Source data are available online for this figure.
Fig 2: FABP4 colocalizes with SARS-CoV-2 replication organelles in human adipocyte cell lines.(A–C) hTERT pre-adipocytes and differentiated adipocytes infected with SARS-CoV-2 (WA1/2020, MOI = 1). (A, B) Relative expression of viral (A) genomic RNA (nucleocapsid, ***p = 0.0002, **p = 0.0018) and (B) sub-genomic RNA (ORF1ab, ***p = 0.0003, *p = 0.0263), normalized to β-actin. (C) Viral loads measured from supernatant using plaque assay. (****p < 0.0001, **p = 0.0024). Data are pooled from two independent experiments (n = 8, biological replicates). Statistical analysis was performed using two-way ANOVA. (D) IL-6 levels in the supernatant of differentiated adipocytes with or without viral infection (MOI = 1), measured by ELISA. Data are pooled from three independent experiments (n = 14, biological replicates, ****p < 0.0001). Statistical analysis was performed using one-way ANOVA. (E–G) Adipocytes were infected at 4, 9, 12, 16, and 20 days post-differentiation (MOI = 1), with measurements taken 48 h post-infection. (E) Viral loads measured by plaque assay; data represent two independent experiments (n = 4, biological replicates, ****p < 0.0001). Statistical analysis was performed using one-way ANOVA. (F) Western blot of viral nucleocapsid, FABP4, and β-actin proteins levels in cell lysates. (G) Quantification of nucleocapsid and FABP4 band intensities normalized to β-actin, representative of two independent experiments (n = 4, biological replicates, ****p < 0.0001, ***p = 0.0001 and 0.0006). Statistical analysis was performed using two-way ANOVA. (H, I) Percent area of lipid droplets in infected cells and neighboring cells, quantified by fluorescence neutral lipid staining (Bodipy). Infected cells identified by (H) nucleocapsid-positive staining and (I) dsRNA-positive staining. Data pooled from two independent experiments (n = 6, biological replicates, ****p < 0.0001, ***p = 0.0001); statistical analysis was performed using a standard t-test. (J) Representative confocal images of infected differentiated adipocytes (MOI = 1), stained for dsRNA (red), lipid droplets (yellow), and nucleus (DAPI, blue). Scale bar = 50 μm; magnified regions = 10 μm (n = 3). (K) Percent lipid droplet area relative to dsRNA-positive area per cell. Pearson correlation coefficient indicated as r. (L, M) Representative confocal images of control and infected adipocytes at 8, 12, 24, and 48 h post-infection, stained for dsRNA (red), lipid droplets (yellow), calnexin (blue), and FABP4 (gray). (L) Merged image of all stains (Scale bar = 50 μm); insets highlight overlap of FABP4, dsRNA, and calnexin (Scale bar = 5 μm). (M) Signal overlap between dsRNA, FABP4, and calnexin, and between FABP4 and calnexin individually (Scale bar = 5 μm). (N–P) Colocalization of target signals over time, represented as Pearson correlation R. Cells infected with MOI = 3 at 8 and 12 hpi; data pooled from two independent experiments (n = 6, biological replicates, ****p < 0.0001). For 24 and 48 hpi, MOI = 1 was used (n = 3) biological replicates. Statistical analysis was performed using one-way ANOVA. Data shown as mean ± s.e.m. Source data are available online for this figure.
Fig 3: FABP4 deficiency reduces virus titers and disrupts replication organelles formation in adipocytes.(A–E) SARS-CoV-2-infected differentiated adipocytes (MOI = 1), treated with either DMSO, BMS309403 (20 μM) or CRE-14 (20 μM). (A) Relative RNA expression of SARS-CoV-2 nucleocapsid, normalized to β-actin. Data are pooled from two independent experiments (n = 8, biological replicates, ****p < 0.0001, *p = 0.0229). (B) Quantification of nucleocapsid band intensity normalized to β-actin. Data are representative of three independent experiments (n = 3, biological replicates, ****p < 0.0001, ***p = 0.0003, *p = 0.0182). (C) Western blot of nucleocapsid and β-actin protein levels in cell lysates. (D) Viral load measured by plaque assay, pooled from two independent experiments (n = 8, biological replicates, ****p < 0.0001), representative of four independent experiments. (E) IL-6 levels in the supernatant of infected adipocytes treated with FABP4 inhibitors, measured by ELISA. Data are pooled from two independent experiments (n = 8, biological replicates, ***p = 0.0004 and 0.0001). For (A), (B), (D), and (E), statistical analysis was performed using two-way ANOVA. (F–H) Infected wild-type (WT) and FABP4-deficient human adipocytes (MOI = 1). (F) Western blot of nucleocapsid, FABP4, and β-actin protein levels in cell lysates. (G) Quantification of nucleocapsid band intensity normalized to β-actin, representative of two independent experiments (n = 3, biological replicates, **p = 0.0015). (H) Viral load measured by plaque assay from supernatants collected 24 and 48 h post-infection. Data are pooled from three independent experiments (n = 9, biological replicates, ****p < 0.0001). Statistical analysis was performed using a standard t-test. (I–L) Infected differentiated adipocytes (MOI = 3, biological replicates, ****p < 0.0001) fixed 48 h post-infection and stained with dsRNA (red), lipid droplets (yellow), and calnexin (blue). (J, K) Representative images of infected cells with (J) inhibitor treatment or (K) genetic deletion of FABP4. Scale bar = 50 μm, magnified regions = 10 μm. (I, L) Percentage dsRNA area and mean fluorescence intensity per cell. Statistical analysis was performed using one-way ANOVA for (I) and a standard t-test for (L) (n = 3, biological replicates, ****p < 0.0001) biological replicates and 11 to 16 images per sample. (M–O) Real-time electric impedance traces and their corresponding median cell index (hours) for (M) and (N) wild-type and FABP4 knockout mouse pre-adipocytes infected with coronavirus OC43 at indicated MOIs. (O) MRC5 cells infected with OC43 and treated with either DMSO or CRE-14. Statistical analysis was performed using a standard t-test (n = 3, biological replicates, ****p < 0.0001, **p = 0.0026). Data are shown as mean ± s.e.m. Source data are available online for this figure.
Fig 4: Pharmacokinetics of FABP4 inhibition in mice and hamsters.(A, B) Circulating concentrations of BMS309403 and CRE-14 following a 30 mg/kg subcutaneous injection in C57BL/6J mice. (C) Circulating concentrations of CRE-14 in Syrian hamsters following a subcutaneous injection of 10 mg/kg. Tables show (Cmax) maximal concentration, (Tmax) time to reach maximal concentration, (T1/2) half-life, and (AUC0-last) area under the curve from time zero to the last quantifiable time point (n = 3, biological replicates). (D) Percent body weight over time and (E) lung viral titer of hamsters infected with SARS-CoV-2 (Ank1 strain, 100 TCID50) with or without BMS309403 treatment (30 mg/kg) (n = 5, biological replicates, *p = 0.0215). Statistical analysis was performed using a standard t-test. (F) Representative H&E staining (scale bar = 5 mm) and (G) Masson’s trichrome staining (scale bar=2 mm) of lung sections from control and infected hamsters with or without CRE-14 treatment (n = 4). (H) Representative IHC CD68 staining of infected hamster lungs (Ank1-Dlt strain, 1000 TCID50) with or without CRE-14 treatment (15 mg/kg), shown at low (Scale bar = 1 mm) and high (Scale bar = 100 μm) magnification. The mid-panel highlights CD68-positive cells. (I) Number of detected cells normalized to lung tissue area per lung and (J) percentage of CD68-positive cells quantified from CD68 IHC staining represented in (H). (H–J: n = 6 lungs from 3 biological replicates – hamsters). Data are shown as mean ± s.e.m. Source data are available online for this figure.
Fig 5: Increase in FABP4 along with biomarkers of COVID-19 disease severity.(A, B) Maximum concentrations of circulating (A) FABP4 (****p < 0.0001, *p = 0.044) and (B) IL-6 (***p = 0.0005) of cohort 2 of COVID-19 patients (n = 166) stratified based on disease severity (moderate: n = 52, severe: n = 21, and critical: n = 42). (C) Circulating levels of C-reactive protein (****p < 0.0001, ***p = 0.0002, *p = 0.0221), (D) leukocytes (****p < 0.0001, **p = 0.0015) and (E) lymphocytes (****p < 0.0001) of COVID-19 patients measured on the day in which the maximum FABP4 concentration was measured (day post symptom onset). Statistical analysis was performed using one-way ANOVA (n = 283 cohort 1, and n = 116 cohort 2). (F–I) Maximum FABP4 concentration pooled from severe and critically ill patients (cohort 1: n = 176, cohort 2: n = 63), stratified based on (F) the presence or absence of comorbidities (listed in Table 3 and Dataset EV2, ****p < 0.0001), (G) age (**p = 0.0011), (H) BMI (***p = 0.0001, **p = 0.0098 and 0.004, *p 0.0263), and (I) the presence or absence of cardiometabolic conditions (diabetes, hypertension, or coronary artery disease, ****p < 0.0001). Statistical analysis for (F), (G) and (I) were performed using Welch’s t-test and one-way ANOVA for (H). Data are shown as the mean ± s.e.m. Source data are available online for this figure.
Supplier Page from OriGene Technologies for FABP4 Human shRNA Plasmid Kit (Locus ID 2167)